TransMedics Group, Inc. - Common Stock (TMDX)

The organ transplant technology specialist significantly exceeded Wall Street's estimates in the fourth quarter.

TransMedics faces allegations from Scorpion Capital of fraud and organ trafficking, while the company rebuffs the claims as baseless market manipulation.

The market kicked off with a notable rally, marking the return of what appears to be a

From a preschool teacher newly inspired to invest at 73 to a lifelong Fool whose Microsoft shares became a 500-bagger, this year-end mailbag edition brims with transformational stories.

As we usher in the new year, market dynamics continue to be shaped by a blend of tax-deferral selling, the January effect, and macro uncertainties.

All 10 underperformed in 2024, but I believe they'll turn things around in 2025.